ZTS vs. MRK, PFE, BMY, RPRX, CORT, JAZZ, PRGO, SUPN, PCRX, and OMER
Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry.
Zoetis vs.
Merck & Co., Inc. (NYSE:MRK) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
Merck & Co., Inc. currently has a consensus price target of $109.19, suggesting a potential upside of 34.27%. Zoetis has a consensus price target of $212.75, suggesting a potential upside of 27.32%. Given Merck & Co., Inc.'s higher probable upside, equities analysts clearly believe Merck & Co., Inc. is more favorable than Zoetis.
In the previous week, Merck & Co., Inc. had 50 more articles in the media than Zoetis. MarketBeat recorded 78 mentions for Merck & Co., Inc. and 28 mentions for Zoetis. Zoetis' average media sentiment score of 1.39 beat Merck & Co., Inc.'s score of 1.34 indicating that Zoetis is being referred to more favorably in the news media.
76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 0.1% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Merck & Co., Inc. received 79 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.91% of users gave Zoetis an outperform vote while only 66.71% of users gave Merck & Co., Inc. an outperform vote.
Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.
Merck & Co., Inc. pays an annual dividend of $3.24 per share and has a dividend yield of 4.0%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.2%. Merck & Co., Inc. pays out 47.2% of its earnings in the form of a dividend. Zoetis pays out 35.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 14 consecutive years and Zoetis has raised its dividend for 14 consecutive years.
Merck & Co., Inc. has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Zoetis has a net margin of 26.86% compared to Merck & Co., Inc.'s net margin of 26.67%. Zoetis' return on equity of 53.82% beat Merck & Co., Inc.'s return on equity.
Summary
Zoetis beats Merck & Co., Inc. on 13 of the 20 factors compared between the two stocks.
Get Zoetis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:ZTS) was last updated on 6/11/2025 by MarketBeat.com Staff
